FindTrial
Sign In

Clinical and Pathological Characteristics and Treatment Outcomes of SMARCA4-Deficient Non-Small Cell Lung Cancer: A Dual-Center Retrospective Analysis

Clinical and pathological features and treatment outcomes of SMARCA4-deficient non-small cell lung cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500114951
Enrollment
Unknown
Registered
2025-12-19
Start date
2025-12-19
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SMARCA4-Deficient Non-Small Cell Lung Cancer

Interventions

Observation group:N/A

Sponsors

Yuebei People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Pathologically diagnosed with non-small cell lung cancer; 2. Loss of SMARCA4 protein expression demonstrated by immunohistochemical staining; 3. Complete baseline imaging data for staging purposes.

Exclusion criteria

Exclusion criteria: 1. Lack of critical clinicopathological data (e.g., survival status, treatment regimen, etc.); 2. Coexistence of other primary malignant tumors.

Design outcomes

Primary

MeasureTime frame
Overall survival;—

Countries

China

Contacts

Public ContactLin Zhou

Yuebei People’s Hospital

zhoulin2002003@126.com+86 751 6913902

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026